10x Genomics to Acquire Scale Biosciences
10x Genomics (Nasdaq: TXG) has announced a definitive agreement to acquire Scale Biosciences, a leader in innovative single cell analysis. The acquisition aims to enhance TXG's Chromium platform by integrating Scale's combinatorial indexing and quantum barcoding technologies.
The deal brings aboard Scale's scientific founders as advisors, including prominent researchers from Stanford University and University of Washington. The acquisition will support TXG's multi-year product roadmap focused on expanding single cell analysis capabilities, making it more powerful, affordable, and accessible to researchers globally.
10x Genomics will maintain support for existing Scale customers and continue key initiatives like the 100 Million Cell Challenge and the Billion Cells Project, while keeping core Scale products available in the market.
10x Genomics (Nasdaq: TXG) ha annunciato un accordo definitivo per acquisire Scale Biosciences, un'azienda leader nell'analisi innovativa delle singole cellule. L'acquisizione mira a potenziare la piattaforma Chromium di TXG integrando le tecnologie di indicizzazione combinatoria e codifica quantistica di Scale.
L'accordo prevede l'ingresso dei fondatori scientifici di Scale come consulenti, tra cui importanti ricercatori della Stanford University e dell'Universit脿 di Washington. Questa acquisizione supporter脿 il piano pluriennale di TXG per espandere le capacit脿 di analisi delle singole cellule, rendendole pi霉 potenti, accessibili e convenienti per i ricercatori di tutto il mondo.
10x Genomics continuer脿 a supportare i clienti attuali di Scale e a portare avanti iniziative chiave come il 100 Million Cell Challenge e il Billion Cells Project, mantenendo disponibili sul mercato i prodotti principali di Scale.
10x Genomics (Nasdaq: TXG) ha anunciado un acuerdo definitivo para adquirir Scale Biosciences, l铆der en an谩lisis innovador de c茅lulas individuales. La adquisici贸n tiene como objetivo mejorar la plataforma Chromium de TXG integrando las tecnolog铆as de indexaci贸n combinatoria y codificaci贸n cu谩ntica de Scale.
El acuerdo incorpora a los fundadores cient铆ficos de Scale como asesores, incluyendo destacados investigadores de la Universidad de Stanford y la Universidad de Washington. Esta adquisici贸n apoyar谩 la hoja de ruta de productos plurianual de TXG, enfocada en ampliar las capacidades de an谩lisis de c茅lulas individuales, haci茅ndolas m谩s potentes, asequibles y accesibles para los investigadores a nivel mundial.
10x Genomics mantendr谩 el soporte para los clientes actuales de Scale y continuar谩 con iniciativas clave como el 100 Million Cell Challenge y el Billion Cells Project, adem谩s de mantener los productos principales de Scale disponibles en el mercado.
10x Genomics (雮橃姢雼�: TXG)臧� 順侅嫚鞝侅澑 雼澕 靹疙彫 攵勳劃 攵勳暭鞚� 靹犽憪欤检瀽鞚� Scale Biosciences毳� 鞚胳垬頃橂姅 斓滌 瓿勳暯鞚� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 鞚胳垬電� Scale鞚� 臁绊暕 鞚鸽嵄鞁� 氚� 鞏戩瀽 氚旍綌霐� 旮办垹鞚� 韱淀暕頃橃棳 TXG鞚� Chromium 頂岆灚韽检潉 臧曧檾頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
鞚措矆 瓿勳暯鞙茧 Stanford 雽�頃欔祼鞕� 鞗岇嫳韯� 雽�頃欔祼鞚� 鞝�氇呿暅 鞐瓣惮鞛愲摛鞚� 韽暔頃� Scale鞚� 瓿柬暀 彀诫鞛愲摛鞚� 鞛愲 鞐暊鞚� 毵￡矊 霅╇媹雼�. 鞚� 鞚胳垬電� 雼澕 靹疙彫 攵勳劃 旮半姤鞚� 頇曥灔頃橃棳 雿� 臧曤牓頃橁碃, 瓴届牅鞝侅澊氅�, 鞝� 靹戈硠 鞐瓣惮鞛愲摛鞚� 靿疥矊 鞝戧芳頃� 靾� 鞛堧弰搿� 頃橂姅 TXG鞚� 雼る厔臧� 鞝滍拡 搿滊摐毵奠潉 歆�鞗愴暊 瓴冹瀰雼堧嫟.
10x Genomics電� 旮办〈 Scale 瓿犼皾 歆�鞗愳潉 鞙犾頃橁碃, 1鞏� 靹疙彫 霃勳爠(100 Million Cell Challenge)瓿� 10鞏� 靹疙彫 頂勲鞝濏姼(Billion Cells Project)鞕� 臧欖潃 欤检殧 鞚措媹靺旐嫲敫岆ゼ 歆�靻嶍晿氅�, Scale鞚� 頃奠嫭 鞝滍拡鞚� 鞁滌灔鞐� 瓿勳啀 鞝滉车頃� 鞓堨爼鞛呺媹雼�.
10x Genomics (Nasdaq : TXG) a annonc茅 un accord d茅finitif pour acqu茅rir Scale Biosciences, un leader dans l'analyse innovante des cellules uniques. Cette acquisition vise 脿 renforcer la plateforme Chromium de TXG en int茅grant les technologies d'indexation combinatoire et de codage quantique de Scale.
L'accord int猫gre les fondateurs scientifiques de Scale en tant que conseillers, incluant des chercheurs 茅minents de l'Universit茅 de Stanford et de l'Universit茅 de Washington. Cette acquisition soutiendra la feuille de route produit pluriannuelle de TXG, ax茅e sur l'expansion des capacit茅s d'analyse des cellules uniques, pour les rendre plus puissantes, abordables et accessibles aux chercheurs du monde entier.
10x Genomics continuera de soutenir les clients actuels de Scale et de poursuivre des initiatives cl茅s telles que le 100 Million Cell Challenge et le Billion Cells Project, tout en maintenant les produits phares de Scale disponibles sur le march茅.
10x Genomics (Nasdaq: TXG) hat eine endg眉ltige Vereinbarung zur 脺bernahme von Scale Biosciences, einem f眉hrenden Unternehmen im Bereich der innovativen Einzelzellanalyse, bekannt gegeben. Die 脺bernahme soll die Chromium-Plattform von TXG durch die Integration von Scales kombinatorischer Indexierung und Quanten-Barcoding-Technologien verbessern.
Im Rahmen des Deals werden die wissenschaftlichen Gr眉nder von Scale, darunter renommierte Forscher der Stanford University und der University of Washington, als Berater an Bord geholt. Die 脺bernahme unterst眉tzt den mehrj盲hrigen Produktfahrplan von TXG, der darauf abzielt, die F盲higkeiten der Einzelzellanalyse zu erweitern und sie f眉r Forscher weltweit leistungsf盲higer, erschwinglicher und zug盲nglicher zu machen.
10x Genomics wird den Support f眉r bestehende Scale-Kunden aufrechterhalten und wichtige Initiativen wie die 100 Million Cell Challenge und das Billion Cells Project fortf眉hren, w盲hrend die Kernprodukte von Scale weiterhin auf dem Markt verf眉gbar bleiben.
- Strategic acquisition enhances TXG's Chromium platform capabilities
- Brings aboard valuable intellectual property in combinatorial indexing and quantum barcoding
- Adds prominent scientific founders as advisors including experts from Stanford and UW
- Expands market reach and accessibility of single cell analysis technology
- Maintains continuity for existing Scale products and customer initiatives
- Integration costs and challenges may impact short-term operations
- Potential overlap in product offerings may require rationalization
Insights
10x Genomics' acquisition of Scale Biosciences strengthens its single cell analysis capabilities, boosting its competitive position in the growing spatial biology market.
This strategic acquisition gives 10x Genomics access to Scale Biosciences' combinatorial indexing and quantum barcoding technologies - critical advancements in single cell analysis that enable researchers to analyze larger cell populations more efficiently. The deal significantly enhances 10x's Chromium platform, its flagship product for analyzing individual cells at scale.
The integration addresses a fundamental challenge in single cell research: balancing throughput with data quality. By incorporating Scale's innovations, 10x can now offer researchers the ability to analyze more cells and samples simultaneously while maintaining the high-quality multiomic data that scientists require.
Scale's technology aligns perfectly with emerging industry trends toward AI-powered medical discoveries, as stated by Scale co-founder Dr. Garry Nolan. The acquisition positions 10x to better serve the growing demand for massive cellular datasets needed to train effective AI models in biological research.
From a competitive standpoint, this acquisition strengthens 10x Genomics' position in the rapidly evolving spatial biology market against competitors like NanoString and Vizgen. By retaining Scale's scientific founders (including prominent researchers from Stanford and University of Washington) as advisors, 10x gains valuable expertise to guide future innovation.
For existing Scale customers, 10x has committed to supporting ongoing experiments and maintaining key Scale products, which should ensure a smooth transition and minimal disruption to research projects.
Acquisition Will Further Expand Chromium's Capabilities
Scale Biosciences was founded by a multidisciplinary team of scientists and technologists with expertise in next generation sequencing, genomics, and bioinformatics. Their unique work in combinatorial indexing and quantum barcoding represents a key advancement in scalable single cell analysis and is now poised to reach more scientists through 10x's innovation roadmap. Scale's scientific founders, all of whom are joining 10x as advisors, are: Professor Garry Nolan at Stanford University, Professors Jay Shendure and Cole Trapnell at University of
"At 10x, we're relentlessly innovating to build a world where single cell analysis is routine, accessible, and scalable at levels previously unimaginable," said Serge Saxonov, CEO of 10x Genomics. "This acquisition is a step towards that vision 鈥� reflecting our commitment to accelerating adoption of single cell technologies. By integrating Scale's inventions with 10x's global platform and innovation engine, we will broaden the capabilities and reach of existing and future products."
By bringing Scale's capabilities into 10x, the company ensures that Scale's technology will reach more researchers, enable more scientific breakthroughs, and support 10x's mission to advance human health. This acquisition will support an ambitious multi-year product roadmap for single cell innovation 鈥� one that aims to dramatically scale both the number of cells and samples that can be analyzed, while preserving the rich, high-quality multiomic data that researchers expect from 10x.
"These inventions were designed to make single cell analysis dramatically more scalable and accessible," said Garry Nolan, PhD, co-founder of Scale Biosciences and Professor at Stanford University. "They have already advanced biological discovery, and with 10x's innovation engine, that impact will only accelerate. This integration will help the research community generate the high-quality data needed to drive AI-powered breakthroughs in medicine."
"We are incredibly proud of what we've built at Scale and its impact advancing biological understanding in single cell analysis. Our integration with 10x will accelerate the adoption of our technology, helping it reach new customers and transformative emerging applications," said Giovanna Prout, President and CEO of Scale Biosciences. "We look forward to 10x building on our pioneering work and supporting a broader global customer base that will drive the next wave of biological discovery."
10x will support current Scale customers with ongoing experiments, as well as initiatives such as the 100 Million Cell Challenge and the Billion Cells Project. In addition, key Scale products will remain on the market.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit or connect with us on , , , or .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s acquisition of Scale Biosciences, Inc., integration activities, potential commercial reach, potential impacts of its products and services and potential products, applications and capabilities. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-Q and 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: [email protected]
Media: [email protected]
View original content to download multimedia:
SOURCE 10x Genomics, Inc.
FAQ
What is the strategic rationale behind 10x Genomics' acquisition of Scale Biosciences?
Who are the key scientific founders joining 10x Genomics from Scale Biosciences?
How will the Scale Biosciences acquisition affect existing Scale customers?
What technologies does Scale Biosciences bring to 10x Genomics?
What is 10x Genomics' plan for Scale Biosciences' technology integration?
